The efficacy of adjuvant therapies in combination with cholinesterase inhibitors for the treatment of Alzheimer's disease
Date of Award
Spring 2020
Degree Name
Master of Medical Science (Physician Assistant)
Department
Physician Assistant; College of Health Sciences
First Advisor
Kimberly Erikson
Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that presents primarily in the elderly with short-term memory loss, cognitive decline and loss of functional ability. The mainstay of treatment includes first-line cholinesterase inhibitors (ChEI) and the addition of memantine in moderate to severe disease. Despite initiation of first-line treatment, patients continue to decline and will eventually require rigorous medical care. Therefore, this review analyzes: in adult patients diagnosed with Alzheimer’s disease [P], are adjuvant treatments in combination with cholinesterase inhibitors [I] more effective in the symptom management of cognitive and functional decline [O] when compared to cholinesterase inhibitors alone [C]?
Recommended Citation
Bohus, Kaitlyn, "The efficacy of adjuvant therapies in combination with cholinesterase inhibitors for the treatment of Alzheimer's disease" (2020). Capstone Showcase. 48.
https://scholarworks.arcadia.edu/showcase/2020/pa/48
Additional Files
Poster Presentation.pptx (1506 kB)Capstone Poster
Poster Presentation Video.mp4 (12995 kB)
Presentation Video
The efficacy of adjuvant therapies in combination with cholinesterase inhibitors for the treatment of Alzheimer's disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that presents primarily in the elderly with short-term memory loss, cognitive decline and loss of functional ability. The mainstay of treatment includes first-line cholinesterase inhibitors (ChEI) and the addition of memantine in moderate to severe disease. Despite initiation of first-line treatment, patients continue to decline and will eventually require rigorous medical care. Therefore, this review analyzes: in adult patients diagnosed with Alzheimer’s disease [P], are adjuvant treatments in combination with cholinesterase inhibitors [I] more effective in the symptom management of cognitive and functional decline [O] when compared to cholinesterase inhibitors alone [C]?